130 related articles for article (PubMed ID: 1405759)
21. The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.
van der Hem KG; Dräger AM; Huijgens PC; Tol C; Devillé W; Langenhuijsen MM
Leukemia; 1994 Feb; 8(2):266-73. PubMed ID: 7508534
[TBL] [Abstract][Full Text] [Related]
22. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
[TBL] [Abstract][Full Text] [Related]
23. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1.
Basu A; Lazo JS
Cancer Res; 1992 Jun; 52(11):3119-24. PubMed ID: 1591725
[TBL] [Abstract][Full Text] [Related]
24. Antineoplastic dolastatins: potent inhibitors of hematopoietic progenitor cells.
Jacobsen SE; Ruscetti FW; Longo DL; Keller JR
J Natl Cancer Inst; 1991 Nov; 83(22):1672-7. PubMed ID: 1749020
[TBL] [Abstract][Full Text] [Related]
25. Effects of dolastatins on human B-lymphocytic leukemia cell lines.
Hu ZB; Gignac SM; Quentmeier H; Pettit GR; Drexler HG
Leuk Res; 1993 Apr; 17(4):333-9. PubMed ID: 8487581
[TBL] [Abstract][Full Text] [Related]
26. Bryostatin induces changes in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic leukemia cells (HL-60).
Kraft AS; Baker VV; May WS
Oncogene; 1987 May; 1(2):111-8. PubMed ID: 3325877
[TBL] [Abstract][Full Text] [Related]
27. Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells.
Phelan SA; Lindberg C; Call KM
Cell Growth Differ; 1994 Jun; 5(6):677-86. PubMed ID: 8086342
[TBL] [Abstract][Full Text] [Related]
28. Effects of bryostatin 1 and calcium ionophore (A23187) on apoptosis and differentiation in human myeloid leukemia cells (HL-60) following 1-beta-D-arabinofuranosylcytosine exposure.
Vrana JA; Rao AS; Wang Z; Jarvis WD; Grant S
Int J Oncol; 1998 Apr; 12(4):927-34. PubMed ID: 9499457
[TBL] [Abstract][Full Text] [Related]
29. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin.
Lilly M; Tompkins C; Brown C; Pettit G; Kraft A
Cancer Res; 1990 Sep; 50(17):5520-5. PubMed ID: 2386956
[TBL] [Abstract][Full Text] [Related]
30. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
31. Different effects of the two protein kinase C activators bryostatin-1 and TPA on growth and differentiation of human monocytic leukemia cell lines.
Steube KG; Grunicke D; Quentmeier H; Drexler HG
Leuk Res; 1993 Oct; 17(10):897-901. PubMed ID: 8412301
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.
Poncet J; Busquet M; Roux F; Pierré A; Atassi G; Jouin P
J Med Chem; 1998 Apr; 41(9):1524-30. PubMed ID: 9554885
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of various protein kinase C activators on protein phosphorylation in human acute myeloblastic leukemia cell line KG-1 and its phorbol ester-resistant subline KG-1a.
Kiss Z; Deli E; Shoji M; Koeffler HP; Pettit GR; Vogler WR; Kuo JF
Cancer Res; 1987 Mar; 47(5):1302-7. PubMed ID: 3469014
[TBL] [Abstract][Full Text] [Related]
34. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.
Wang Z; Su ZZ; Fisher PB; Wang S; VanTuyle G; Grant S
Exp Cell Res; 1998 Oct; 244(1):105-16. PubMed ID: 9770354
[TBL] [Abstract][Full Text] [Related]
35. Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells.
Dale IL; Bradshaw TD; Gescher A; Pettit GR
Cancer Res; 1989 Jun; 49(12):3242-5. PubMed ID: 2720677
[TBL] [Abstract][Full Text] [Related]
36. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.
Mohammad RM; Pettit GR; Almatchy VP; Wall N; Varterasian M; Al-Katib A
Anticancer Drugs; 1998 Feb; 9(2):149-56. PubMed ID: 9510501
[TBL] [Abstract][Full Text] [Related]
37. Effects of TPA, bryostatin 1, and retinoic acid on PO-B, AP-1, and AP-2 DNA binding during HL-60 differentiation.
Davis AF; Meighan-Mantha RL; Riegel AT
J Cell Biochem; 1997 Jun; 65(3):308-24. PubMed ID: 9138088
[TBL] [Abstract][Full Text] [Related]
38. Induction of the c-ski proto-oncogene by phorbol ester correlates with induction of megakaryocyte differentiation.
Namciu S; Lieberman MA; Stavnezer E
Oncogene; 1994 May; 9(5):1407-16. PubMed ID: 8152801
[TBL] [Abstract][Full Text] [Related]
39. Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.
Szallasi Z; Denning MF; Smith CB; Dlugosz AA; Yuspa SH; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Nov; 46(5):840-50. PubMed ID: 7969070
[TBL] [Abstract][Full Text] [Related]
40. Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.
Grant S; Pettit GR; Howe C; McCrady C
Leukemia; 1991 May; 5(5):392-8. PubMed ID: 2033960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
